Novartis drug is already approved. They are currently focusing on distribution and undertaking other studies to increase market share in the current treatable population. As I understand, Novartis are still interested in having their treatment offered earlier in the treatment process, which may open the door for Veyonda at some point in the future. Looks like a interesting 3rd and 4th quarter for holders.
Novartis drug is already approved. They are currently focusing...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $42.51K | 418.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5591 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |